Skip to content

Apogee Therapeutics, Inc. APGE Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$274.62M-7.3%-$255.84M-0.9%-$253.67M-6.7%-$237.67M-15.7%-$205.39M-12.8%
$1.61M+14.2%$1.41M+30.5%$1.08M+48.2%$731K+99.2%$367K+94.2%
$52.31M+13.0%$46.28M+10.3%$41.96M+16.8%$35.92M+18.7%$30.27M+29.7%
-$234.54M-3.1%-$227.45M+2.2%-$232.48M-5.3%-$220.74M-17.4%-$188.02M-9.8%
$5.15M+1.2%$5.09M-12.9%$5.84M+14.0%$5.12M+344%
-$227.91M-26.9%-$179.57M
$807.04M+104%$396.49M+502%$65.9M+41.6%$46.54M+2.6%$45.36M-90.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Apogee Therapeutics, Inc. generate?
Apogee Therapeutics, Inc. (APGE) generated -$234.5M in operating cash flow over the trailing twelve months.
What is Apogee Therapeutics, Inc.'s free cash flow?
After $5.1M of capital expenditures, Apogee Therapeutics, Inc.'s free cash flow was -$232.6M over the trailing twelve months, down 35.0% year over year.
Where does Apogee Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Apogee Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.